Discover how Novartis’s investigational NMDA modulator MIJ821 offers rapid antidepressant effects for treatment‑resistant depression with fewer dissociative, cognitive, and cardiovascular side effects than ketamine and esketamine.
Learn what zuranolone is, how it works as a fast-acting GABAA-modulating antidepressant, and why it’s a breakthrough for major depressive disorder and postpartum depression, with key clinical trial data on onset, durability, and dosing.